
    
      In this open-label pilot study, patients are randomized to 1of the following 4 arms for 24
      weeks:

      Arm 1 (40 patients): DLV plus ZDV plus IDV. Arm 2 (40 patients): DLV plus IDV plus 3TC*. Arm
      3 (40 patients): DLV plus ZDV plus IDV plus 3TC. Arm 4 (40 patients): ZDV plus IDV plus 3TC.

        -  Dose determined by body weight. Patients may opt to continue on study for 24 additional
           weeks at the discretion of the investigator.
    
  